Gut bacterial quorum sensing molecules and their association with inflammatory bowel disease: Advances and future perspectives.

Inflammatory Bowel Disease (IBD) is an enduring inflammatory disease of the gastrointestinal tract (GIT). The complexity of IBD, its profound impact on patient's quality of life, and its burden on healthcare systems necessitate continuing studies to elucidate its etiology, refine care strategies, improve treatment outcomes, and identify potential targets for novel therapeutic interventions. The discovery of a connection between IBD and gut bacterial quorum sensing (QS) molecules has opened exciting opportunities for research into IBD pathophysiology. QS molecules are small chemical messengers synthesized and released by bacteria based on population density. These chemicals are sensed not only by the microbial species but also by host cells and are essential in gut homeostasis. QS molecules are now known to interact with inflammatory pathways, therefore rendering them potential therapeutic targets for IBD management. Given these intriguing developments, the most recent research findings in this area are herein reviewed. First, the global burden of IBD and the disruptions of the gut microbiota and intestinal barrier associated with the disease are assessed. Next, the general QS mechanism and signaling molecules in the gut are discussed. Then, the roles of QS molecules and their connection with IBD are elucidated. Lastly, the review proposes potential QS-based therapeutic targets for IBD, offering insights into the future research trajectory in this field. [Display omitted] • The connection between IBD and gut bacterial QS molecules opens exciting opportunities for IBD pathophysiology research. • QS molecules interact with inflammatory pathways, rendering them potential therapeutic targets for IBD management. • 3-oxo-C12:2-HSL exerts anti-inflammatory and tight junction integrity-preserving characteristics. • Aryl hydrocarbon receptors (AhR) and paraoxonases (PONs) are observed to be dysfunctional in several IBD patients. • 3-oxo-C12:2-HSL molecule, AhR, and PONs may be explored as promising targets for IBD management. [ABSTRACT FROM AUTHOR]